Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenance to Progression in NDMM by Cytogenetic Risk
By
Dana-Farber Cancer Institute
FEATURING
Paul Richardson
By
Dana-Farber Cancer Institute
FEATURING
Paul Richardson
Login to view comments.
Click here to Login